• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics, Inc. - Common Stock (NQ:DRMA)

2.180 -0.140 (-6.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dermata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
December 29, 2025
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
December 24, 2025
Via ACCESS Newswire
News headline image
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
December 04, 2025
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 14, 2025
Via ACCESS Newswire
News headline image
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
October 02, 2025
Via ACCESS Newswire
News headline image
Dermata to Present on BioPub on January 31, 2025
January 29, 2025
Via ACCESS Newswire
News headline image
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
December 16, 2024
Via ACCESSWIRE
News headline image
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
December 10, 2024
Via ACCESSWIRE
News headline image
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
September 18, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
September 17, 2025
Via ACCESS Newswire
News headline image
Life Science Virtual Investor Forum Agenda Announced for September 18th
September 16, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
December 03, 2024
Via ACCESSWIRE
News headline image
Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
September 16, 2025
Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
September 10, 2025
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 13, 2025
Via ACCESS Newswire
News headline image
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
July 08, 2025
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 13, 2024
Via ACCESSWIRE
News headline image
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 14, 2025
Via ACCESS Newswire
News headline image
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
April 15, 2025
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
March 27, 2025
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
March 17, 2025
Via ACCESS Newswire
News headline image
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
February 25, 2025
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
January 22, 2025
Via ACCESS Newswire
News headline image
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
January 21, 2025
Via ACCESS Newswire
News headline image
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
November 15, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for November 14th
November 12, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
November 11, 2024
– Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com – 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
October 08, 2024
Via ACCESSWIRE
News headline image
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
September 17, 2024
Via ACCESSWIRE
News headline image
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
September 16, 2024
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap